Figure 1. MRI and CT scan of patient at time of diagnosis and after Imatinib treatment.

Top panel: Contrast-enhanced nuclear magnetic resonance of the abdomen (left) and whole body ¹⁸F-FDG PET/CT of the patient with a duodenal GIST (arrow) at time of diagnosis (right). The mass displayed contact with various structures (left) and manifested intense metabolic activity (right, SUV 6.3). Middle panel: Contrast-enhanced nuclear magnetic resonance (left) of the patient abdomen at time of post-neoadjuvant surgery. The mass was reduced in size allowing to perform segmental duodenectomy safely. Whole body ¹⁸F-FDG PET/CT of the patient (right) that after a single month neoadjuvant Imatinib showed absent metabolic activity, attesting optimal drug sensitivity. Bottom panel: patient history timeline.